The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions

@article{Turner2018TheUD,
  title={The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions},
  author={L. Turner},
  journal={Perspectives in Biology and Medicine},
  year={2018},
  volume={61},
  pages={24 - 7}
}
  • L. Turner
  • Published 2018
  • Medicine
  • Perspectives in Biology and Medicine
  • abstract:Hundreds of businesses and clinics in the United States are engaged in direct-to-consumer marketing of unproven and unlicensed stem cell–based interventions. This essay provides an overview of this marketplace, examines advertising techniques companies use to draw clients and legitimate marketing claims, and summarizes the roles the Food and Drug Administration (FDA) and other agencies are supposed to play in regulating the direct-to-consumer marketplace for stem cell interventions… CONTINUE READING
    Characterizing Direct-to-Consumer Stem Cell Businesses in the Southwest United States
    • 6
    • Highly Influenced
    International Expert Consensus on a Cell Therapy Communication Tool: DOSES
    • 12
    • PDF

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 67 REFERENCES
    Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.
    • 200
    • PDF
    ClinicalTrials.gov, stem cells and 'pay-to-participate' clinical studies.
    • 32
    Direct‐to‐Consumer Stem Cell Marketing and Regulatory Responses
    • 19
    US stem cell clinics, patient safety, and the FDA.
    • 40
    The unregulated commercialization of stem cell treatments: a global perspective
    • 28
    Regulating autologous adult stem cells: the FDA steps up.
    • 49
    • Highly Influential
    U.S. Regulation of Stem Cells as Medical Products
    • 41